The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 22%.
Jyong Biotech Ltd MENS
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.
read at $2.26
Jyong Biotech Ltd holds its Accumulation at $2.26.
- PHPhase · the trend structure carries the Accumulation label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 92 days |
| Price | $2.26 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | N/A |
The business, in plain words · what the numbers mean
| Profit margin | 0.0% currently unprofitable |
| Current ratio | 0.45 below 1 — short-term bills exceed liquid assets |
| Market cap | $172M |
| Employees | 27 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Taiwan and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in MENS's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 8 May2026 | Ro Khanna | Democrat | buy | 1K–15K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $2.07 | -16.9% | · | $831 | -16.9% |
| 2 months | $2.49 | -30.9% | · | $691 | -30.9% |
| 3 months | $2.15 | -20.0% | · | $800 | -20.0% |
| 6 months | $26.64 | -93.5% | · | $65 | -93.5% |
Historical returns from market close data. Past performance does not guarantee future results.